Your browser is no longer supported. Please, upgrade your browser.
TTPH Tetraphase Pharmaceuticals, Inc. monthly Stock Chart
Tetraphase Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-18.50 Insider Own14.90% Shs Outstand9.27M Perf Week-3.13%
Market Cap18.75M Forward P/E- EPS next Y-2.15 Insider Trans26.32% Shs Float6.04M Perf Month12.22%
Income-62.70M PEG- EPS next Q-1.28 Inst Own42.30% Short Float6.11% Perf Quarter110.17%
Sales7.90M P/S2.37 EPS this Y16.80% Inst Trans290.04% Short Ratio0.19 Perf Half Y-10.14%
Book/sh2.96 P/B0.84 EPS next Y45.80% ROA-121.70% Target Price- Perf Year-73.10%
Cash/sh3.45 P/C0.72 EPS next 5Y- ROE-210.90% 52W Range0.56 - 10.40 Perf YTD-11.74%
Dividend- P/FCF- EPS past 5Y14.40% ROI-297.80% 52W High-76.15% Beta2.32
Dividend %- Quick Ratio3.60 Sales past 5Y-4.10% Gross Margin45.60% 52W Low342.86% ATR0.21
Employees67 Current Ratio3.70 Sales Q/Q38.50% Oper. Margin- RSI (14)51.98 Volatility6.27% 8.72%
OptionableNo Debt/Eq0.00 EPS Q/Q82.00% Profit Margin- Rel Volume0.06 Prev Close2.53
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.90M Price2.48
Recom3.50 SMA20-1.43% SMA5012.57% SMA200-0.01% Volume123,205 Change-1.98%
May-07-20Upgrade Gabelli & Co Sell → Hold
Mar-17-20Downgrade Gabelli & Co Hold → Sell
Jan-24-20Downgrade Gabelli & Co Buy → Hold
Oct-31-19Upgrade Gabelli & Co Hold → Buy
Jan-07-19Resumed B. Riley FBR Buy $3
Sep-06-18Upgrade WBB Securities Speculative Buy → Buy $7
Feb-22-18Initiated WBB Securities Speculative Buy $6
Feb-14-18Reiterated Stifel Buy $13 → $6
Feb-14-18Reiterated H.C. Wainwright Buy $17 → $6
Feb-12-18Initiated B. Riley FBR, Inc. Buy $11
Nov-06-17Reiterated H.C. Wainwright Buy $15 → $17
Oct-09-17Reiterated Stifel Buy $13 → $13
Aug-28-17Initiated Piper Jaffray Overweight $14
Jul-26-17Upgrade Stifel Hold → Buy $8 → $15
Jul-11-17Initiated H.C. Wainwright Buy $15
Mar-09-17Reiterated Stifel Hold $5 → $7
May-13-16Reiterated Wedbush Outperform $8 → $4
May-13-16Downgrade Gabelli & Co Buy → Hold $7
Nov-19-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy
Sep-09-15Downgrade Stifel Buy → Hold
Jun-25-20 08:26AM  
Jun-24-20 07:30AM  
Jun-22-20 12:14PM  
Jun-10-20 07:30AM  
Jun-04-20 09:22AM  
Jun-03-20 06:50PM  
Jun-02-20 07:45AM  
Jun-01-20 04:51PM  
May-29-20 08:43AM  
May-28-20 08:24AM  
May-27-20 08:55PM  
May-22-20 07:10AM  
May-21-20 09:55PM  
May-12-20 10:17AM  
May-07-20 07:50PM  
May-06-20 12:30PM  
May-05-20 04:39PM  
Apr-30-20 05:18PM  
Apr-29-20 11:30PM  
Apr-28-20 06:56PM  
Apr-27-20 01:50PM  
Apr-21-20 07:55PM  
Apr-20-20 09:56PM  
Apr-14-20 06:18PM  
Apr-10-20 02:50PM  
Apr-07-20 10:00AM  
Apr-02-20 04:46PM  
Mar-24-20 11:36AM  
Mar-19-20 01:55PM  
Mar-18-20 05:41PM  
Mar-17-20 06:35PM  
Mar-16-20 05:10PM  
Mar-12-20 07:30AM  
Mar-05-20 12:30PM  
Jan-23-20 07:24AM  
Jan-22-20 06:45PM  
Dec-02-19 08:40PM  
Nov-12-19 05:15PM  
Nov-05-19 08:00AM  
Nov-01-19 04:18PM  
Oct-30-19 08:00AM  
Sep-26-19 07:00AM  
Sep-25-19 07:00AM  
Sep-22-19 08:06AM  
Sep-12-19 01:11PM  
Aug-09-19 03:23PM  
Aug-08-19 05:55PM  
Jul-25-19 10:33AM  
Jun-24-19 07:00AM  
Jun-17-19 03:14PM  
Jun-13-19 08:44PM  
Jun-12-19 04:01PM  
Jun-10-19 07:00AM  
May-29-19 07:00AM  
May-09-19 09:23AM  
May-08-19 05:35PM  
May-06-19 04:13AM  
May-02-19 07:00AM  
May-01-19 07:03AM  
Apr-30-19 07:00AM  
Apr-28-19 10:08AM  
Apr-25-19 10:33AM  
Apr-08-19 07:00AM  
Apr-05-19 06:22PM  
Apr-03-19 08:00AM  
Apr-01-19 04:03PM  
Mar-15-19 02:13AM  
Mar-14-19 04:20PM  
Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LA JOLLA PHARMACEUTICAL CO10% OwnerJun 19Buy2.62234,698613,9931,085,000Jun 22 05:16 PM
Freund John GordonDirectorDec 10Sale2.1914,50731,7700Dec 12 09:35 PM
Freund John GordonDirectorDec 10Sale2.195241,1480Dec 12 09:35 PM
Macdonald GuyDirectorDec 06Sale2.255,73512,903250Dec 09 05:10 PM
Macdonald GuyDirectorDec 05Sale2.341,8704,3775,985Dec 09 05:10 PM